RxDoctor Payments Data

Madison Andrews, MD

Geriatric Medicine · Oklahoma City, OKNPI 1376036921

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Amgen accounts for 82.2% of it on its own, with 4 other manufacturers making up the rest.

$489in general payments, 2019–2025

Across 12 payments — averaging $40.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$402
  • Astellas Pharma US Inc$30
  • Vertex$22
  • AbbVie$19
  • Merck$15

What the payments were for

  • Food & beverage$489100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen8$402
Astellas Pharma US Inc1$30
Vertex1$22
AbbVie1$19
Merck1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$489 in reported general payments places this provider in the 70th percentile of 25 geriatric medicine providers in Oklahoma.

See all geriatric medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$206,771
Medicare patients
427
Services billed
2,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban59$41,410
JardianceEmpagliflozin43$39,232
MounjaroTirzepatide32$37,381
OzempicSemaglutide37$33,932
JanuviaSitagliptin Phosphate28$31,077
FarxigaDapagliflozin Propanediol26$13,868
TrulicityDulaglutide11$12,377
RybelsusSemaglutide11$9,666
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,166
EntrestoSacubitril/Valsartan12$8,242
Advair HfaFluticasone Propion/Salmeterol19$7,860
OxycontinOxycodone Hcl13$6,975
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$5,145
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$4,252
Escitalopram Oxalate181$2,942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$15$31,07728 claims
AbbVieSynthroid$19$2,01522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 25 geriatric medicine providers in Oklahoma.

Other geriatric medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →